Senseonics (NYSE:SENS) announced today that it received FDA clearance for its next-generation Eversense 365 CGM system.

The U.S. FDA cleared Senseonic Holdings Inc.’s Eversense 365, the first continuous glucose monitor to last a full year with a single sensor rather than the 10 days to two weeks typical for wearable ...

The FDA has cleared Senseonics and Ascensia Diabetes Care's Eversense 365 Glucose Monitoring System. This system is designed for Type 1 and Type 2 diabetics 18 and older and will be the first ...

Eversense 365 is a fully-implantable CGM with a 365-day sensor, making it the first 1-year CGM option for diabetes management ...

Eversense 365 cleared in the U.S. as an integrated continuous glucose monitoring (iCGM) system for people with diabetes With a single sensor, the Eversense 365 system provides one year of use, versus ...

Senseonics, a medtech manufacturer developing long-term, implantable continuous glucose monitoring (CGM) systems, and ...

After collecting FDA green lights for 90- and 180-day versions, the agency has cleared the latest generation of the Eversense ...

A Maryland-based healthcare company is turning heads so far during Tuesday’s session after the it was announced that the ...

Senseonics and Ascensia Diabetes Care have announced that the U.S. Food and Drug Administration has cleared the next-generation Eversense 365 CGM, the first one-year CGM system ...

Senseonics Holdings, Inc. (NYSE: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with ...

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of ...

Senseonics has raised over $40 million to fund the US launch of its Eversense continuous glucose monitor (CGM). Most of the funding has come from major shareholder Roche through its ...